You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer

Article info

Article menu

Download PDFPDF

Poster
IGCS20_1171
180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer
Free

Authors

Citation

Yue Y, Shen H, Lu C, et al
180 An open-label randomized active-controlled phase ii clinical study to assess efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer
International Journal of Gynecologic Cancer 2020;30:A78.

Publication history

  • First published November 13, 2020.
Online issue publication 
November 13, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.